Reovirus T3D preferentially kills tumor cells expressing Ras oncogenes and has shown great promise as an anticancer agent in various preclinical tumor models. Here, we investigated whether reovirus can infect and kill tumor cell cultures and tissue fragments isolated from resected human colorectal tumors, and whether this was affected by the presence of endogenous oncogenic KRAS. Tissue fragments and single-cell populations isolated from human colorectal tumor biopsies were infected with reovirus virions or with intermediate subviral particles (ISVPs). Reovirus virions were capable of infecting neither single-cell tumor cell populations nor small fragments of intact viable tumor tissue. However, infection of tumor cells with ISVPs resulted in transient viral protein synthesis, irrespective of the presence of oncogenic KRAS, but this did not lead to the production of infectious virus particles, and tumor cell viability was largely unaffected. ISVPs failed to infect intact tissue fragments. Thermolysin treatment of tumor tissue liberated single cells from the tissue and allowed infection with ISVPs, but this did not result in the production of infectious virus particles. Immunohistochemistry on tissue microarrays showed that junction adhesion molecule 1, the major cellular reovirus receptor, was improperly localized in the cytoplasm of colorectal tumor cells and was expressed at very low levels in liver metastases. This may contribute to the observed resistance of tumor cells to reovirus T3D virions. We conclude that infection of human colorectal tumor cells by reovirus T3D requires processing of virions to ISVPs, but that oncolysis is prevented by a tumor cell response that aborts viral protein synthesis and the generation of infectious viral particles, irrespective of KRAS mutation status.
Introduction
Activating mutations in the KRAS proto-oncogene are found in approximately 30% of all human tumors. Recent evidence suggests that the sustained presence of oncogenic KRAS is required for maintenance of the transformed and malignant properties of several types of tumor cells. [1] [2] [3] This makes KRAS, or KRAS-activated signaling intermediates, attractive targets for therapeutic intervention. Reovirus T3D is an oncolytic virus that kills susceptible cells by inducing apoptosis. 4 We have recently shown that oncogenic KRAS sensitizes human and mouse colorectal tumor cells to apoptosis induction by reovirus T3D. 5, 6 Alternatively, KRAS may facilitate virus replication. 7 Reovirus T3D has shown great preclinical therapeutic efficacy in the treatment of several types of subcutaneous tumors and metastatic lesions formed by tumor cell lines. [8] [9] [10] [11] [12] Based on this preclinical evidence, the antitumor activity of reovirus T3D is currently being tested in clinical trials. 13 Many novel therapeutics that show great promise as antitumor compounds in preclinical experiments fail to fulfill this promise in clinical trials. Work from our own group and from others has shown that reovirus T3D can efficiently kill colorectal tumor cell lines and cell linederived tumors in mice. 5, 6, 9, 12 In the present report, we have evaluated the potential of reovirus T3D to infect and kill tumor cells and tissue fragments freshly isolated from primary human colorectal tumors and their liver metastases. Furthermore, we have assessed whether virus replication and tumor cell killing are associated with the presence of oncogenic KRAS. Finally, we determined the expression and localization of the major reovirus receptor, junction adhesion molecule 1 (JAM1) 14 in normal colon and in primary human colorectal tumors and their paired liver metastases.
Materials and methods

Tumor samples
Patients who underwent a resection for primary colon cancer or for colorectal liver metastases from January 2004 to August 2006 were included in the study. The study was approved by the medical ethical committee of our institute. All patients gave their informed consent to the use of their tumor tissue for the purpose of this study. Directly following resection, the specimens were taken to the pathology department where a part of the tumor was excised for experimentation. The biopsy was mechanically dissociated using scalpels and vigorous trituration to yield small fragments (o1 mm 3 ) and single cells. In some cases, where indicated, the tissue fragments were incubated with thermolysin (0.05% in 10 mM Hepes pH 7.2, 37 1C, 1 h). The suspension was then filtered through a 70 mm pore size nylon cell strainer to separate the tissue fragments from the single cells. Tissue fragments and single cells were cultured separately in 96-well plates in Dulbecco's Modified Eagle's Medium/Ham F12 (1/1) (Dulbecco, ICN Pharmaceuticals, Costa Mesa, CA, USA) supplemented with 15% (v/v) fetal calf serum, 2 mM glutamine, 0.1 mg ml À1 streptomycin, 100 U ml À1 penicillin and 2% Ultroser G (PALL Life Sciences, Portsmouth, UK) at 37 1C in a humidified atmosphere containing 5% CO 2 .
Cell line, virus and intermediate subviral particles
The human colorectal cancer cell line HCT116 was purchased from American Type Culture Collection (CCL-247). HCT116 cells were cultured in Dulbecco's Modified Eagle's Medium (Dulbecco) supplemented with 5% (v/v) fetal calf serum, 2 mM glutamine, 0.1 mg ml À1 streptomycin and 100 U ml À1 penicillin. All cells were kept at 37 1C in a humidified atmosphere containing 5% CO 2 . Reovirus T3D was purchased from American Type Culture Collection (Teddington, UK) (VR-824). The virus was propagated and purified as described previously. 5 Intermediate subviral particles (ISVPs) were freshly prepared by treating purified virions with chymotrypsin just prior to infection (200 mg ml À1 ; Roche Diagnostics, Penzberg, Germany) for 60 min at 37 1C. Digestion was stopped by the addition of PMSF (Calbiochem, Amsterdam, The Netherlands) to 2.5 mM at 4 1C.
Fluorescence-activated cell sorting analysis Primary tumor cells (2 Â 10 5 ) were washed twice with PBS containing 2% FCS and were resuspended in PBS-FCS 2% containing anti-hEpCam/Trop1 (1:200; R&D systems, Abingdon, UK) or isotype control antibody. After 1 h incubation at 4 1C, the cells were washed twice with 2% FCS-PBS and were resuspended in 2%FCS-PBS containing goat-anti-mouse Fab2-488 (1:200; Dako, Heverlee, Belgium). Following a 1 h incubation at 4 1C, the samples were washed twice and were immediately analyzed by flow cytometry using a FACScalibur (BD Biosciences, San Diego, CA, USA).
Western blotting
To 10 ml of a reovirus or ISVP stock, sample buffer was added and the samples were run on a 10% sodium dodecyl sulfate-polyacrylamide gel for western blotting. After blotting, the membrane was washed and incubated for 1 h with polyclonal rabbit anti-reovirus serotype 3 serum. After washing, the membrane was incubated for 1 h with swine anti-rabbit-RPO (Dako) (1:5000). The signals were visualized using an enhanced chemiluminescence system (Roche) 24 h after labeling and cell extracts or tumor fragments were prepared in sample buffer and were analyzed with electrophoresis on long 45 cm sodium dodecyl sulfatepolyacrylamide gel. Gels were dried and exposed to radiographic film. Quantity One (Biorad, Hercules, CA, USA) software was used to quantify the signal intensities. The ratios between the viral s band and the cellular protein running approximately 5 kDa above s were calculated in each case.
Plaque assay
Plaque assays were performed exactly as described. 5 Viability assay Cells were plated on 96-wells plates and calcein (Invitrogen, Leek, The Netherlands) was added to 2.5 mM on days 1-4 (15 min, 37 1C). Cells were harvested and washed once with PBS and were resuspended in PBS. The percentage of viable (fluorescent) cells was analyzed by flow cytometry.
DNA extraction, PCR and sequence analysis Genomic DNA was extracted from frozen tumor specimens corresponding to the tissue fragments and cell populations that were analyzed for reovirus replication. The dissected tissue was suspended in extraction buffer (1 M Tris, 0.5 M EDTA and 10% SDS) containing proteinase K (1 mg ml
À1
) and was incubated at 56 1C for 48 h. Proteinase K was freshly added every 12 h. The solution was extracted twice with a 25:24:1 mixture of phenol-chloroform-isoamylalcohol. Genomic DNA was precipitated with ethanol, pelleted and resuspended in TE (Tris-HCl 10 mM, EDTA 1 mM). Target sequences encompassing codons 12, 13 and 61 of the KRAS gene and codon 600 of the BRAF gene were amplified by nested PCR in 384-well plates. Sequencing was performed using the Big Dye terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Warrington, UK), according to the manufacturer's instructions. Analysis of the products was performed on an ABI Prism 377 DNA Sequencer (PE Biosystems, Foster City, CA, USA). All target sequences were amplified in duplicate by independent PCR reactions and sequencing was performed using both the forward and reverse sequencing primer. Only if a mutation was found in both independently amplified fragments, it was considered a real mutation and not a PCR artifact. The primer sequences will be supplied upon request.
Tissue microarray A tissue microarray (TMA) was made to analyze the expression of JAM1 in normal colon epithelium and in CRC cells in the primary tumor and the corresponding liver metastasis. We collected representative paraffinembedded tissue blocks from neoplastic and nonneoplastic regions and the TMA was constructed as described previously in detail. 15 In brief, samples from surgical resections of 61 patients of whom normal colon, primary CRC and corresponding CRC liver metastasis were available were selected for preparing a TMA. For each patient, nine cylindrical tissue cores were included in the TMA; three from the normal colon, three from the primary CRC and three from the corresponding liver metastasis. Immunostaining was performed using standard procedures. After incubation with 3% hydrogen peroxide, antigen retrieval was achieved by boiling in 10 mM citrate buffer, pH 6.0. Sections were blocked with 5% goat serum in TBS and incubated with an anti-JAM1 antibody (H-80, sc-25629; Santa Cruz Biotechnology, Heidelberg, Germany) at 4 1C overnight. HRP-conjugated secondary antibodies (DPVM-55HRP; Immunologic, Duiven, The Netherlands) were detected with 3,3 0 -diaminobenzidine substrate (D4418; Sigma, Saint Louis, MO, USA). Slides were counterstained with hematoxylin and rinsed with water, dehydrated in ethanol, cleared in xylene and coverslipped. The localization and intensity of JAM1 staining was determined in each separate tissue core by two independent experienced observers blinded to the cores' identities. Membranous staining of JAM1 was scored as positive or negative. When a tissue core displayed weak and focal positivity in less than 5% of the total number of tumor cells, it was classified as negative. Cytoplasmic staining was scored as 0: no staining, 1: weak staining, 2: moderate staining and 3: strong staining. The average scores of the three biopsies were calculated. Next, single-cell cultures freshly isolated from tumor biopsies were infected either with virions or with ISVPs (20 pfu per cell) and reovirus protein synthesis was assessed over time. Reovirus protein synthesis could clearly be detected 1 day after infection of the tumor cell cultures with ISVPs, but not with virions (Figures 4a and b) . Infection with ISVPs yielded robust reovirus protein synthesis 1 day after infection in six out of eight tumor cell populations tested. However, in all these cultures, reovirus protein synthesis had dropped dramatically on day 2 and was undetectable by day 3 (Figures 4a and b) . Despite the fact that viral protein synthesis was clearly detectable in ISVP-infected tumor cells, they showed only a marginal nonsignificant increase in the production of infectious virus particles over a period of 4 days (1.4-fold amplification of the input dose) (Figure 4c) . Similarly, virion-infected tumor cells did not significantly amplify the input dose (1.8-fold) (Figure 4c) . Interestingly, only one of the six tumor cell populations that sustained temporary reovirus replication also showed a temporary loss of cell viability as measured by FACScan analysis of calcein-stained cells (Figure 4d) . Thus, when compared to virions, reovirus ISVPs show a greatly enhanced ability to infect single-cell cultures of colorectal tumors, but viral protein synthesis is rapidly aborted, which allows most tumor cell cultures to survive infection.
Results
Isolation
Freshly isolated tumor tissue is resistant to infection with reovirus virions and ISVPs
Next, we tested whether tumor cells in the context of tumor tissue could be infected with reovirus virions or ISVPs. Following infection, viral protein synthesis was assessed by [
35 S]methionine labeling experiments. Tumor fragments from 30 independent colorectal tumors were tested, and none of the tumors showed detectable reovirus protein synthesis following infection with either virions or ISVPs (Figure 3c ). In eight of these tumors (27%), we detected activating mutations in KRAS (G12D (3 Â ), G12V (2 Â ), G13D (1 Â ), G12S (1 Â ), G12R (1 Â )), while 2 (7%) tumors harbored an activated BRAF allele (V600E (2 Â ). Also at later time points (up to 8 days), we failed to detect reovirus protein synthesis in any of the virion-or ISVP-infected tissue fragments. Thus, ISVPs can infect single-cell cultures of freshly isolated tumor cells, but they fail to penetrate tumor tissue.
Finally, we tested whether degradation of the extracellular matrix in tumor tissue fragments by the protease thermolysin would allow tumor cell infection by reovirus. Thermolysin was previously successfully used for the isolation of primary epithelial cells from human intestinal tissue. 16 Thermolysin treatment greatly increased the yield of single tumor cells from tumor tissue (data not shown), and allowed infection of the isolated single cells with ISVPs but not with virions (Figure 4f) . Thus, thermolysin treatment of tumor tissue liberates single cells from the tissue and makes them available for infection with ISVPs. However single-cell populations isolated with or without thermolysin treatment did not show differences in their ability to sustain reovirus protein synthesis, or in their ability to produce infectious virus particles (Figures 4f  and g ). Thus, even in the absence of extracellular matrix and stromal tissue, freshly isolated primary colorectal cancer cells are very inefficient in sustaining reovirus replication and virus production. Furthermore, the relatively inefficient generation of virus progeny by freshly isolated tumor cells (Figure 4c ) was unaffected by inclusion of thermolysin in the isolation procedure (Figure 4g ). Rather, virus yield in the thermolysin-treated samples was even lower than that in the nontreated samples, although these differences were not statistically significant.
Human primary colorectal tumors and liver metastases display aberrant localization of JAM1
The major reovirus virion receptor is a tight junction molecule called JAM1. JAM1 localizes to cell-cell contacts in layers of epithelial and endothelial cells and its expression is a major determinant of cellular sensitivity to reovirus infection.
14 In contrast, ISVPs infect target cells independently of JAM1, as the JAM1-binding head domain of the viral s1 attachment protein is lost during ISVP generation. 17 The finding that freshly isolated colorectal tumor cells are resistant to infection with virions, but not ISVPs, prompted us to test JAM1 expression in a series of primary human colorectal carcinomas and paired liver metastases. Normal colon tissue adjacent to the primary tumor was used as a positive control. Paired samples of 61 patients were available from the Pathology database. After construction and evaluation of the TMA, a total of 52 normal colon samples, 61 primary tumor samples and 53 liver metastasis samples were available for analysis. Immunohistochemical analysis of JAM1 expression on the TMA revealed that JAM1 is localized at epithelial cell-cell contacts in normal colonic enterocytes, as expected ( Figure 5 ). In contrast, JAM1 staining was predominantly cytoplasmic in primary colorectal tumors and in liver metastases, but it was not observed at the cell-cell contacts between tumor cells ( Figure 5 ). Only 4/61 primary tumors and 2/53 liver metastases displayed weak focal JAM1 staining at cell-cell contacts. Finally, JAM1 expression was markedly and significantly lower in the liver metastases than in the paired primary tumors and in control colon tissue. This is relevant, because novel therapeutics are required for the treatment of (liver) metastases rather than primary tumors. Thus, mislocalization and low-level expression of JAM1 may contribute to the resistance of human colorectal tumor cells to reovirus T3D.
Discussion
Reovirus infects target cells through interaction of the head domain of the attachment protein s1 with JAM1.
14 However, our results show that JAM1 is localized in the cytoplasm of colorectal tumor cells. This is in contrast to normal epithelial cells where JAM1 is localized at the cell surface, notably at intercellular tight junctions. At present, it is not known to what extent JAM1 contributes to the determination of cell and tissue tropism displayed by reovirus T3D, and to what extent JAM1 is accessible to reovirus within tight junctions. 18 Nevertheless, JAM1 remains the best characterized reovirus T3D receptor to date.
14 Therefore, further work is needed to establish a functional link between aberrant JAM1 localization and expression in CRC tumors and the resistance of CRC cells to reovirus infection in vitro and in vivo. Infection of colorectal tumor cells independently of JAM1 could be established by proteolytic processing of reovirus virions to ISVPs. The C-terminal head fragment of the s1 viral attachment protein, which binds to JAM1 14 is released during this process, 17 whereas the s1 tail domain, which binds to sialic acid moieties on cell surface glycoproteins and/or glycolipids 19, 20 is retained. Sialic acid binding is likely to be critical in the JAM1-independent infection of tumor cells by ISVPs and, moreover, it is essential for the induction of apoptosis in tumor cells. 21 During the generation of ISVPs the sialic acid-binding capacity, as measured by erythrocyte agglutinating activity, is markedly stimulated, 17 and this may explain why ISVPs, but not virions, can infect freshly isolated colorectal tumor cells, although they fail to kill them.
The intestinal epithelium produces a mucinous layer of cell surface sialic acid-rich glycoconjugates, which acts as a physical barrier to pathogen invasion. Indeed, most epithelial cells lining the digestive tract are protected from reovirus infections by the mucus layer and only the M-cells in the Peyer's patches, which are devoid of a mucus layer are prone to be infected. Many colorectal tumors retain the capacity to form a mucus layer 22, 23 and this may interfere with the infection of tumor cells by oncolytic viruses like reovirus T3D. 24 Interestingly, s1 from reovirus T3D possesses a latent glycosyl hydrolase activity that is uncovered during the generation of ISVPs. It has been suggested that ISVPs utilize this activity to hydrolyze (part of) the glycosidic portion of the mucus layer to allow infection of otherwise resistant cells. 25 It is presently not known how this activity affects binding of reovirus to sialic acid moieties within the mucus layer. Taken together, we propose that ISVP generation may be a prerequisite for efficient tumor cell infection and oncolysis of colorectal tumors in vivo. However, our results also show that even if it is feasible to infect tumor cells with ISVPs, tumor cell killing is prevented by the rapid shutdown of viral protein synthesis. In the series of freshly isolated tumor cell cultures analyzed here, the presence of oncogenic KRAS could not prevent the shutdown of reovirus protein synthesis. The extracellular matrix and stromal cell populations form an additional physical barrier for viral access to tumor cells such that neither virions nor ISVPs can breach.
In conclusion, our results suggest that the infection of colorectal tumor cells in tumor tissue is hindered by at least three independent barriers ( Figure 6 ). First, stromal tissue forms a physical barrier between virus particles and tumor cells. Second, tumor cells are resistant to infection A paraffin-embedded tissue microarray containing samples of normal human colon, primary colorectal carcinomas and colorectal liver metastases from the same patients was processed for immunohistochemistry using an antibody directed against human JAM1. JAM1 localized to cell-cell contacts in normal human colon, as expected. However, JAM1 in primary human colorectal carcinomas and in liver metastases was not observed at cell-cell contacts, but in the cytoplasm. In addition, the overall staining intensity in liver metastases was markedly and significantly lower than in the primary tumors (Po0.001). Membrane staining was scored as positive (1) or negative (0). Cytoplasmic staining was scored as 0: no staining, 1: weak staining, 2: moderate staining and 3: strong staining. The average scores of three biopsies per tumor were calculated and plotted.
by reovirus virions, possibly due to aberrant JAM1 localization and/or expression. This can be overcome by virion processing into ISVPs. Third, colorectal tumor cells rapidly abort reovirus protein synthesis and fail to produce infectious virus progeny. The presence of oncogenic KRAS does not prevent the shutdown of viral protein synthesis, but is more likely to affect the course of a productive infection by facilitating apoptosis induction. Tumors that produce proteases that can process virions to ISVPs, may allow subsequent tumor cell infection. Once infected, colorectal tumor cells rapidly abort reovirus protein synthesis. The presence of oncogenic KRAS is not sufficient to allow sustained reovirus protein synthesis. Rather, activated KRAS is more likely to affect the late stages of a productive infection by facilitating apoptosis induction. 5, 6 
